Active ingredient:  Dexamphetamine

Form/Route:  Tablets/Oral

Recommended studies:  2 studies

1. Type of study: Fasting
   Design: Single-dose, two-way crossover in-vivo
   Strength: 10 mg
   Subjects: Normal healthy males and females, general population.
   Additional Comments:

2. Type of study: Fed
   Design: Single-dose, two-way crossover in-vivo
   Strength: 10 mg
   Subjects: Normal healthy males and females, general population.
   Additional comments:

Analytes to measure: Dexamphetamine in plasma

Bioequivalence based on (90% CI): Dexamphetamine

Waiver request of in-vivo testing: 2.5 mg and 5 mg based on (i) acceptable bioequivalence studies on the 10 mg strength, (ii) proportionally similar across all strengths, and (iii) acceptable in vitro dissolution testing of all strengths.

Dissolution test method and sampling times:

Please note that a Dissolution Methods Database is available to the public at the OGD website at http://www.fda.gov/cder/ogd/index.htm. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.

Recommended Feb 2008